BioSyent (RX.V) Saham Harga
BioSyent Harga
Pendapatan tumbuh 19,3% per tahun selama 19 tahun terakhir menjadi 43,05 Juta. CAD. Laba per saham tumbuh 18,6% per tahun selama 19 tahun terakhir. margin bersih BioSyent saat ini 20,9%, turun dari 21,9% beberapa tahun lalu. BioSyent saat ini menawarkan imbal hasil dividen sekitar 1,17%. Rasio pembayaran sekitar 25% dari laba. Dividen tumbuh 71,0% per tahun selama 3 tahun terakhir. Target harga median analis adalah 16,83 CAD, di bawah harga saat ini sebesar 1,3%. Dari 7 analis, 6 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham BioSyent
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham BioSyent
Pertanyaan yang sering diajukan tentang saham BioSyent
The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.
Biosyent Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biosyent Inc in the market include pharmaceutical companies like Apotex Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V.
Biosyent Inc is a pharmaceutical company based in Canada. It was founded in 2004 and has since become a leader in the specialty pharmaceutical industry. The company focuses on acquiring or in-licensing niche pharmaceutical products, with a goal to provide reliable and effective therapeutic options to patients and healthcare professionals. Biosyent Inc has a successful track record of commercializing pharmaceutical products and has established a strong presence in the Canadian market. With a commitment to high-quality medications, Biosyent Inc continuously strives to meet the evolving healthcare needs of the population.
Biosyent Inc has achieved significant milestones since its inception. The company has successfully launched and commercialized multiple pharmaceutical and healthcare products in Canada. This includes obtaining regulatory approvals for important drugs, expanding their product portfolio, and establishing strategic partnerships with global pharmaceutical companies. Biosyent Inc has also demonstrated consistent revenue growth and increased market share, highlighting its strong performance in the industry. With their commitment to innovation and delivering high-quality products, Biosyent Inc continues to contribute to the advancement of healthcare and pharmaceuticals.
Biosyent Inc is primarily present in Canada and the United States.
Biosyent Inc is a pharmaceutical company that values innovation, sustainability, and customer-centricity. Their corporate philosophy revolves around providing high-quality, niche pharmaceutical products to meet the evolving healthcare needs of patients. With a focus on sourcing and licensing unique product opportunities, Biosyent Inc has built a strong reputation as a reliable partner within the healthcare industry. By utilizing their expertise in regulatory affairs and product commercialization, Biosyent Inc strives to improve patient outcomes while delivering value to their shareholders.
Analis saat ini menetapkan target harga rata-rata 16,83 CAD untuk saham BioSyent (median: 16,83 CAD), yaitu -1,3 % terhadap harga terbaru. Konsensus didasarkan pada 7 peringkat analis.
7 analis saat ini menilai saham BioSyent: 6 merekomendasikan beli, 1 tahan, dan 0 jual. Untuk 2026, analis memperkirakan BioSyent menghasilkan pendapatan 73,20 Juta. CAD dan laba per saham 1,05 CAD.
Dengan kurs saat ini, saham BioSyent diperdagangkan pada 10,89 EUR (17,05 CAD).
Saham BioSyent (RX.V) tercatat di 2 bursa, termasuk: Toronto (RX.V).
Biosyent Inc is a pharmaceutical company headquartered in Canada that focuses on the development, marketing, and distribution of innovative products. The company specializes in medications in the areas of dermatology, gastroenterology, urology, and pain management. The business strategy of Biosyent Inc is to bring new products to the market that are needed by the growing number of patients and healthcare providers. In addition, the company also produces generics, which it offers at lower costs than the originals. Biosyent Inc aims to improve the lives of patients through better healthcare solutions. The company is active in various regions and works with partners in Canada, the US, and Europe. Through targeted investments and marketing initiatives, Biosyent Inc has managed to expand its reach and diversify its offerings. The company collaborates closely with physicians, pharmacies, and customers to tailor its offerings to their needs. In the field of dermatology, the company offers preparations for acne, eczema, psoriasis, and other skin problems. In gastroenterology, Biosyent Inc has developed medications that can be used to treat gastrointestinal diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. In urology, the company offers a solution for erectile dysfunction, and in pain management, it provides effective opioid antagonists in the form of nasal sprays and sublingual tablets. In addition to pharmaceutical products, Biosyent Inc also offers diagnostics and a solution for measuring urine flow. To further improve its products, the company also invests in researching new technologies and therapy forms. The company has a strong research and development department that works closely with the marketing and sales departments. Biosyent Inc strategically invests in the search for new active ingredients and solutions to continue offering its customers innovative products. Furthermore, the company works on optimizing its production processes and increasing its efficiency. The divisions of Biosyent Inc include: - Dermatology - Gastroenterology - Urology - Pain management Biosyent Inc. focuses on diversifying its offerings and producing innovative products that meet the needs of patients. Through the use of new technologies and procedures, the company aims to continue growing and strengthening its position in the market.
Pendapatan diperkirakan dari BioSyent adalah 73,20 Juta. CAD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari BioSyent adalah 11,81 Juta. CAD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) BioSyent saat ini adalah 16,26. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham BioSyent.
Rasio harga-terhadap-penjualan (PSR) BioSyent saat ini adalah 2,62. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham BioSyent.
Skor Kualitas AlleAktien untuk BioSyent adalah 10/10.
ISIN dari BioSyent adalah CA0906901081. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari BioSyent adalah A1J6DY. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari BioSyent adalah RX.V. Simbol ticker digunakan untuk memperdagangkan saham BioSyent di bursa saham.
Saham BioSyent
Kelompok Peer BioSyent
BioSyent Ticker
BioSyent FIGI
Semua metrik fundamental dan analisis mendalam BioSyent
Analisis saham kami untuk saham BioSyent mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari BioSyent. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.